Le Xu1, Yuan Chang1, Huimin An1, Yu Zhu2, Yuanfeng Yang1, Jiejie Xu3. 1. Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China. 2. Department of Urology, Shanghai Cancer Center, Fudan University, Shanghai, China. 3. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China. Electronic address: jjxufdu@fudan.edu.cn.
Abstract
PURPOSE: APOBEC3B is a member of the cytosine deaminase family, which converts cytosine to uracil during RNA editing and retrovirus or retrotransposon restriction. Recent evidence has revealed that APOBEC3B-catalyzed genomic DNA deamination could provide genetic fuel for cancer development, metastasis, and even treatment resistance. The aim of this study was to assess the association between APOBEC3B expression and the risk of recurrence after surgery in patients with renal cell carcinoma (RCC). METHODS: We retrospectively enrolled 299 consecutive patients with RCC who underwent nephrectomy at a single center in 2008. Clinicopathologic variables and recurrence-free survival (RFS) were recorded. APOBEC3B expression levels were determined by immunohistochemistry in tumor tissues. Kaplan-Meier method was applied to compare survival curves. Cox regression models were fitted to analyze the effect of prognostic factors on RFS. The Harrell concordance index was calculated to assess predictive accuracy. RESULTS: High APOBEC3B expression was associated with an increased risk of recurrence in patients with clear cell RCC (ccRCC) (P<0.001) rather than in patients with non-ccRCC (P = 0.247). After backward elimination, APOBEC3B expression was identified as an independent prognostic factor for RFS in patients with clear cell histology (P = 0.016). The predictive accuracy of the Leibovich prognostic score was improved when APOBEC3B expression was incorporated. Notably, the improvement in prediction mainly took place in patients with low-risk disease defined by the Leibovich score. CONCLUSIONS: High APOBEC3B expression is an independent predictor of recurrence in patients with ccRCC, and the prognostic value is most prominent in those with low-risk disease.
PURPOSE:APOBEC3B is a member of the cytosine deaminase family, which converts cytosine to uracil during RNA editing and retrovirus or retrotransposon restriction. Recent evidence has revealed that APOBEC3B-catalyzed genomic DNA deamination could provide genetic fuel for cancer development, metastasis, and even treatment resistance. The aim of this study was to assess the association between APOBEC3B expression and the risk of recurrence after surgery in patients with renal cell carcinoma (RCC). METHODS: We retrospectively enrolled 299 consecutive patients with RCC who underwent nephrectomy at a single center in 2008. Clinicopathologic variables and recurrence-free survival (RFS) were recorded. APOBEC3B expression levels were determined by immunohistochemistry in tumor tissues. Kaplan-Meier method was applied to compare survival curves. Cox regression models were fitted to analyze the effect of prognostic factors on RFS. The Harrell concordance index was calculated to assess predictive accuracy. RESULTS: High APOBEC3B expression was associated with an increased risk of recurrence in patients with clear cell RCC (ccRCC) (P<0.001) rather than in patients with non-ccRCC (P = 0.247). After backward elimination, APOBEC3B expression was identified as an independent prognostic factor for RFS in patients with clear cell histology (P = 0.016). The predictive accuracy of the Leibovich prognostic score was improved when APOBEC3B expression was incorporated. Notably, the improvement in prediction mainly took place in patients with low-risk disease defined by the Leibovich score. CONCLUSIONS: High APOBEC3B expression is an independent predictor of recurrence in patients with ccRCC, and the prognostic value is most prominent in those with low-risk disease.
Authors: Artur A Serebrenik; Gabriel J Starrett; Sterre Leenen; Matthew C Jarvis; Nadine M Shaban; Daniel J Salamango; Hilde Nilsen; William L Brown; Reuben S Harris Journal: Proc Natl Acad Sci U S A Date: 2019-10-14 Impact factor: 11.205
Authors: Jeffrey R Wagner; Özlem Demir; Michael A Carpenter; Hideki Aihara; Daniel A Harki; Reuben S Harris; Rommie E Amaro Journal: J Chem Inf Model Date: 2018-09-10 Impact factor: 4.956
Authors: Artur A Serebrenik; Prokopios P Argyris; Matthew C Jarvis; William L Brown; Martina Bazzaro; Rachel I Vogel; Britt K Erickson; Sun-Hee Lee; Krista M Goergen; Matthew J Maurer; Ethan P Heinzen; Ann L Oberg; Yajue Huang; Xiaonan Hou; S John Weroha; Scott H Kaufmann; Reuben S Harris Journal: Clin Cancer Res Date: 2020-02-14 Impact factor: 12.531
Authors: Ke Shi; Özlem Demir; Michael A Carpenter; Jeff Wagner; Kayo Kurahashi; Reuben S Harris; Rommie E Amaro; Hideki Aihara Journal: Sci Rep Date: 2017-12-12 Impact factor: 4.379
Authors: Brandon Leonard; Gabriel J Starrett; Matthew J Maurer; Ann L Oberg; Mieke Van Bockstal; Jo Van Dorpe; Olivier De Wever; Jozien Helleman; Anieta M Sieuwerts; Els M J J Berns; John W M Martens; Brett D Anderson; William L Brown; Kimberly R Kalli; Scott H Kaufmann; Reuben S Harris Journal: Clin Cancer Res Date: 2016-03-25 Impact factor: 12.531
Authors: Gabriel J Starrett; Elizabeth M Luengas; Jennifer L McCann; Diako Ebrahimi; Nuri A Temiz; Robin P Love; Yuqing Feng; Madison B Adolph; Linda Chelico; Emily K Law; Michael A Carpenter; Reuben S Harris Journal: Nat Commun Date: 2016-09-21 Impact factor: 14.919